Erlocip 100mg :
What is Erlocip used for?
Erlocip tablets 100mg are used to treat non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and grows more slowly than small cell lung cancer (SCLC). NSCLC is associated with a mutation in the gene for Epidermal Growth Factor receptor (EGFR) and treatment of NSCLC with Erlocip tablets 100mg is only effective where an EGFR mutation is present in the tumour cells.
Erlocip 100mg are used for treatment of locally advanced (stage III) or metastatic (stage IV) NSCLC either as first-line treatment, as monotherapy maintenance treatment for stable disease after 4 cycles of standard platinum-based first-line chemotherapy or after failure of at least one prior chemotherapy regimen. Erlocip tablets 100mg are also used to treat locally advanced, unresectable (inoperable) or metastatic pancreatic cancer in combination with gemcitabine, an anti-cancer drug used for chemotherapy. Advanced pancreatic cancer has a very poor survival rate and Erlocip tablets 100mg in combination with gemcitabine can improve the survival rate.
How does Erlocip work?
Erlocip tablets 100mg contain erlotinib, a potent inhibitor of tyrosine kinase, an enzyme that phosphorylates a protein inside a cell, which is the way many cell processes are regulated.
Tyrosine kinases (TK) are cell surface receptors for many cellular messengers including growth factors and erlotinib in Erlocip tablets 100mg acts as a potent inhibitor of the Epidermal Growth Factor receptor (EGFR).
EGF stimulates cell growth, proliferation and differentiation in normal cells. It acts by binding with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors.
When EGF binds to EGFR, the receptor undergoes a shape change, which activates TK activity by phosphorylation of its substrates within the cell and this is the first step in a complex cell signalling pathway involved in cell proliferation and survival.
Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place. However, the mutation associated with NSCLC leaves the receptor in a state that is constantly activated or turned on (constitutively activated) even when EGF is not bound to the receptor.
This results in cells that are stimulated to constantly proliferate and survive leading to NSCLC. Over-expression of the EGFR is thought to be associated with malignant transformation and metastasis of pancreatic cancer, due to the pancreatic cells being over stimulated to proliferate and grow. Erlotinib in Erlocip tablets 100mg works by blocking the intracellular phosphorylation of EGFR, which blocks the signalling pathway for cell proliferation and survival in NSCLC cells and pancreatic cancer cells. This action of Erlotinib in Erlocip tablets 100mg blocks the proliferation of the tumour cells and induces cell death, which results in tumour regression.
What does Erlocip contain?
Erlocip tablets contains the active ingredient erlotinib hydrochloride 100mg, a potent inhibitor of tyrosine kinase cell surface receptor for Epidermal Growth Factor receptor (EGFR), used to treat NSCLC and advanced pancreatic cancer.
Treating non-small cell lung cancer (NSCLC) with Erlocip
Erlocip tablets 100mg contain erlotinib, a tyrosine kinase inhibitor that is used to treat NSCLC, the most common form of lung cancer. NSCLC is epithelial in origin and sub-types include adenocarcinoma, derived from the cells that line the alveoli (air sacs) making up the majority of all NSCLC (40%), squamous cell carcinoma derived from the bronchi (25-30%) and large cell undifferentiated carcinoma that can appear in any part of the lung and spreads rapidly (10-15%).
NSCLC is associated with a mutation in the gene for Epidermal Growth Factor receptor (EGFR). Several different types of mutation have been identified and treatment of NSCLC with Erlocip tablets 100mg is only effective where an EGFR mutation is present in the tumour cell. Erlocip tablets 100mg are used for treatment of locally advanced (stage III) or metastatic (stage IV) NSCLC either as first-line treatment, as monotherapy maintenance treatment for stable disease after 4 cycles of standard platinum-based first-line chemotherapy or after failure of at least one prior chemotherapy regimen.
Epidermal Growth Factor stimulates cell growth, proliferation and differentiation in normal cells and binds with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors. Binding of EGF to its receptor triggers the first step in a complex cell signalling pathway involved in cell proliferation and survival. Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place.
However, the mutation associated with NSCLC leaves the receptor in a state that is constantly activated or turned on (constitutively activated) even when EGF is not bound to the receptor.
This results in cells that are stimulated to constantly proliferate and survive leading to NSCLC. Erlotinib in Erlocip tablets 100mg works by blocking the intracellular signalling pathway for cell proliferation and survival, thereby inhibiting the proliferation of the tumour cells and reinstating programmed cell death, which results in tumour regression.
Erlocip for pancreatic cancer
Erlocip tablets 100mg contain erlotinib, a tyrosine kinase inhibitor that is used to treat locally advanced, unresectable (inoperable) or metastatic pancreatic cancer in combination with gemcitabine an anti-cancer drug used for chemotherapy. Advanced pancreatic cancer is one of the most difficult to treat cancers and has a very poor survival rate, as it is usually only detected at an advanced stage.
Over-expression of the EGFR is thought to be associated with malignant transformation and metastasis of pancreatic cancer, due the pancreatic cells being over stimulated to proliferate and grow. Epidermal Growth Factor stimulates cell growth, proliferation and differentiation in normal cells and binds with high affinity to its cell surface receptor EGFR, which belongs to the TK family of receptors.
Binding of EGF to its receptor triggers the first step in a complex cell signalling pathway involved in cell proliferation and survival. Normally EGFR activation is regulated and therefore, cell proliferation is controlled and programmed cell death (apoptosis) takes place. Erlotinib in Erlocip tablets 100mg works by blocking the intracellular signalling pathway for cell proliferation and survival, thereby inhibiting the proliferation of the tumour cells and reinstating programmed cell death, which results in tumour regression.
What are the side effects of Erlocip?
The most commonly reported side effects when taking Erlocip tablets 100mg include, rash, acne, nausea, vomiting, diarrhoea, abdominal pain, loss of appetite with anorexia, infection (including pneumonia, sepsis, and cellulitis), cough, eye irritation with conjunctivitis, fatigue, depression. Other side effects include gastrointestinal bleeding, dry or cracked skin. Persistent diarrhoea may lead to dehydration, potassium depletion and impaired kidney function.
When should Erlocip not be used?
You should not use Erlocip tablets 100mg if you:
are allergic to erlotinib or any ingredients in Erlocip
are pregnant or are breastfeeding
have kidney or liver disease
are having immunisation with live vaccine
use contact lenses and/or have a history of eye problems
have gastrointestinal problems particularly diarrhoea as this can worsen with Erlocip
have prior history of peptic ulceration or diverticular disease as this can increase risk of gastrointestinal perforation
are a smoker
have interstitial lung disease
are taking medicines that interact with Erlocip, including corticosteroids and NSAIDs for pain and inflammation, statins for high cholesterol, anticoagulants like warfarin, the immunosuppressant cyclosporine, verapamil for hypertension, proton pump inhibitors like omeprazole, antifungals like ketoconazole, antibiotics like ciprofloxacin, erythromycin, clarithromycin, rifampicin, anticonvulsants like phenytoin, carbamazepine, ranitidine for reflux, St. John’s Wort
What medications interact with Erlocip?
Several medications interact with Erlocip tablets 100mg price and should either not be taken while you are taking Erlocip or only after discussion and instruction from your doctor:
Drugs that cause a serious reaction with Erlocip: corticosteroids and NSAIDs can increase risk of gastrointestinal perforation; statins for high cholesterol can increase risk of myopathy (muscular weakness), anticoagulants like warfarin cause increased bleeding
Drugs that affect Erlocip: the immunosuppressant cyclosporine, verapamil for hypertension, proton pump inhibitors like omeprazole, antifungals like ketoconazole, antibiotics like ciprofloxacin, erythromycin, clarithromycin, rifampicin, anticonvulsants like phenytoin, carbamazepine, ranitidine for reflux, St. John’s Wort
Drugs that are affected by Erlocip: anticoagulants like warfarin,
How should Erlocip be taken?
You should take your buy Erlocip tablets 100mg swallowed whole with a glass of water at least one hour before or two hours after the ingestion of food.
The dose you take and for how long depends on what you are being treated for and your doctor’s recommendation. For pancreatic cancer you should take your Erlocip tablets 100mg in combination with gemcitabine.
You should continue to take your Erlocip tablets 100mg until your disease becomes worse or you show signs of toxicity from the medication, dependent on your doctor’s recommendation.
How long should you take Erlocip?
You should continue to take your Erlocip tablets 100mg until your disease becomes worse or you show signs of toxicity from the medication, dependent on your doctor’s recommendation.
Missed dose of Erlocip :
If you miss a dose of Erlocip tablets 100mg take it as soon as you remember, unless it is time to take the next dose, then skip the missed dose. Do not take a double dose.
How should Erlocip be stored?
You should store your Erlocip below 25°C in a cool dry place.
Buy Now: Buy Erlocip 100mg Online
Comments
Post a Comment